CME

Evidence-Based Clinical Updates in the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

By June 14, 2017No Comments
Evidence-Based Clinical Updates in the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - G411

Evidence-Based Clinical Updates in the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

 

Take Pre-Test    Take Post-test

For information about AMA PRA Category 2 CreditTM, you may consult page 10 of the AMA’s booklet “The Physicians Recognition Award and credit system: Information for accredited providers and physicians – 2010 Revision” found here.

The aim of the project is to ensure hematology care teams participating in new value-based reimbursement models have an accurate understanding of the evidence and roles of new therapies for relapsed/refractory Chronic Lymphocytic Leukemia (CLL), as well as best supportive care practices to promote therapy adherence, quality of life, and reduction of unanticipated healthcare utilization (specifically ED visits and hospitalizations).

At the conclusion of this activity, participants should be able to:
  • Re-evaluate current treatment approaches for patients with relapsed/refractory CLL in light of newly emerging clinical data
  • Personalize the supportive care strategies for patients with relapsed/refractory CLL based on selected treatment and relevant clinical and patient-reported symptom experience
  • Evaluate population level trends regarding symptom experiences and the effectiveness of supportive care strategies for CLL in the relapsed/refractory settings to inform practice and determine future research questions

DOWNLOAD PDF

Download Activity

VIEW ON SLIDESHARE

 

This activity is supported by an independent educational grant from Genentech BioOncology. Activity ID: G-411

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.